Why Quest Diagnostics Incorporated (DGX) Stock Is Up Today

Quest Diagnostics Incorporated (DGX) is up 3.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a mix of fresh growth commentary and continued investor interest in Quest’s new consumer health initiatives. A likely driver is management’s upbeat tone at a September 14 investor conference, alongside ongoing attention around the company’s plan to bring lab ordering into the Apple Health app later this year.

Details:

Quest announced on September 9 that Apple Health app users in the U.S. will be able to buy biomarker lab testing from Quest directly in the app and receive results there, expanding its consumer-facing reach.

At a September 14 healthcare conference, management discussed company strategy and performance, with conference coverage highlighting broad-based momentum, stronger physician-channel utilization, and fast consumer business growth.

Quest entered this stretch with solid operating momentum after its July quarterly report, when it posted double-digit revenue growth and raised its full-year 2026 revenue and EPS guidance.

An analyst price-target increase earlier in September may also have helped sentiment, even without a rating change, as investors looked for additional upside after recent execution gains.

Sources:

Quest Diagnostics Newsroom, Quest Diagnostics Investor Relations, Benzinga, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$DGX Insider Trading Activity

$DGX insiders have traded $DGX stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.

Here’s a breakdown of recent trading of $DGX stock by insiders over the last 6 months:

MICHAEL E PREVOZNIK (SVP & General Counsel) has made 0 purchases and 3 sales selling 22,677 shares for an estimated $5,513,082.
J. E. DAVIS (CEO and President) has made 0 purchases and 2 sales selling 20,000 shares for an estimated $4,368,600.
KARTHIK KUPPUSAMY (SVP, Clinical Solutions) sold 8,147 shares for an estimated $1,629,400
MARK E DELANEY (SVP & Chief Commercial Officer) sold 1,600 shares for an estimated $376,288

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive DGX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$DGX Hedge Fund Activity

We have seen 523 institutional investors add shares of $DGX stock to their portfolio, and 515 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JPMORGAN CHASE & CO added 3,520,438 shares (+inf%) to their portfolio in Q2 2026, for an estimated $746,156,834
PRICE T ROWE ASSOCIATES INC /MD/ removed 853,001 shares (-13.5%) from their portfolio in Q2 2026, for an estimated $180,793,561
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 773,711 shares (+inf%) to their portfolio in Q2 2026, for an estimated $163,988,046
BOSTON PARTNERS added 732,241 shares (+18.3%) to their portfolio in Q2 2026, for an estimated $155,198,479
EDGEPOINT INVESTMENT GROUP INC. added 586,496 shares (+35.3%) to their portfolio in Q2 2026, for an estimated $124,307,827
VICTORY CAPITAL MANAGEMENT INC removed 575,866 shares (-27.1%) from their portfolio in Q2 2026, for an estimated $122,054,798
FMR LLC added 456,517 shares (+48.5%) to their portfolio in Q2 2026, for an estimated $96,758,778

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$DGX Government Contracts

We have seen $130,081,699 of award payments to $DGX over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

VISN 7 REFERENCE LAB SERVICES: $8,250,000
REFERENCE LAB TESTING - ADD AND EXERCISE OPTION: $3,025,981
REFERENCE LAB TESTS: $2,748,684
REFERENCE LAB TESTS: $2,700,000

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$DGX Congressional Stock Trading

Members of Congress have traded $DGX stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $DGX stock by members of Congress over the last 6 months:

SENATOR ALAN ARMSTRONG has traded it 2 times. They made 2 purchases worth up to $30,000 on 03/30, 03/27 and 0 sales.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$DGX Price Targets

Multiple analysts have issued price targets for $DGX recently. We have seen 5 analysts offer price targets for $DGX in the last 6 months, with a median target of $225.0.

Here are some recent targets:

Eric Coldwell from Baird set a target price of $229.0 on 04/22/2026
Luke Sergott from Barclays set a target price of $230.0 on 04/22/2026
David Macdonald from Truist Securities set a target price of $225.0 on 04/22/2026
Kevin Caliendo from UBS set a target price of $220.0 on 04/22/2026
Elizabeth Anderson from Evercore ISI Group set a target price of $210.0 on 04/08/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.